AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 15948814
Drug: Immediate-release omeprazole
RxNorm normalized name: aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Immediate-release omeprazole (twice daily dosing 20 and 40 mg)
Trial: 15948814
Drug: Immediate-release omeprazole
RxNorm normalized name: aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Immediate-release omeprazole (40 mg bedtime dosing)
Trial: 15948814
Drug: Pantoprazole (twice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pantoprazole (twice daily dosing 40 mg)
Trial: 8678062
Drug: Anticoagulant citrate
RxNorm normalized name: ANTICOAGULANT CITRATE DEXTROSE
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Anticoagulant citrate dextrose-A (ACD) (0.113 mol/L citrate)
Trial: 8678062
Drug: Hypertonic tri-sodium
RxNorm normalized name: alginic acid
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypertonic tri-sodium citrate (TSC) (1.6 mol/L citrate)
Trial: 6401229
Drug: Oral isosorbide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral isosorbide dinitrate (ISDN) and topical 2% nitroglycerin ointment (NO)
Trial: 24174275
Drug: landiolol hydrochloride
RxNorm normalized name: Landiolol Hydrochloride
DrugBank: Landiolol (DB12212)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: landiolol hydrochloride 0.125 mg/kg
Trial: 22770832
Drug: Readiness to
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Readiness to change behavior for 2 daily servings of milk
Trial: 22770832
Drug: Readiness to
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Readiness to change behavior for 4 daily servings of milk
Trial: 16243988
Drug: Granisetron 0.1
RxNorm normalized name: granisetron 0.1 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Granisetron 0.1 mg plus Dexamethasone 8 mg (G+D)
Trial: 16243988
Drug: Ondansetron 4
RxNorm normalized name: ondansetron 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ondansetron 4 mg plus Dexamethasone 8 mg (O+D)
Trial: 12195324
Drug: Wireless capsule
RxNorm normalized name: careless weed pollen extract
DrugBank: Amaranthus palmeri pollen (DB10459)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wireless capsule endoscopy (CE)
Trial: 23654110
Drug: 3% L-arabinose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3% L-arabinose
Trial: 23654110
Drug: 5% L-arabinose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% L-arabinose
Trial: 23654110
Drug: 10% L-arabinose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10% L-arabinose
Trial: 23654110
Drug: L-arabinose (daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-arabinose (daily for six months)
Trial: 21713377
Drug: Intracoronary adenosine
RxNorm normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intracoronary adenosine administration
Trial: 18718892
Drug: FOLFIRI (irinotecan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FOLFIRI (irinotecan 180 mg/m² on day 1 + 5-fluorouracil 400 mg/m² bolus and 600 mg/m² 22-h infusion + leucovorin 200 mg/m² on days 1-2, every 2 weeks)
Trial: 18718892
Drug: FUIRI (irinotecan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FUIRI (irinotecan 80 mg/m² + 5-fluorouracil 2,250 mg/m² 48-h infusion, weekly)
Trial: 17008196
Drug: Nicotine patches
RxNorm normalized name: NICOTINE 7 mg in 1 g TRANSDERMAL PATCH [Sielkin QUIT SMOKING NICOTINE PATCHES]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotine patches (21 mg)
Trial: 17008196
Drug: Nicotine lozenges
RxNorm normalized name: nicotine Oral Lozenge
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotine lozenges (4 mg)
Trial: 9714485
Drug: Surgical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical treatment of aortic coarctation
Trial: 7978588
Drug: Nasal midazolam
RxNorm normalized name: midazolam Nasal Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal midazolam (0.25 mg/kg)
Trial: 2657523
Drug: Topical benzocaine
RxNorm normalized name: benzocaine Topical Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical benzocaine 20% gel
Trial: 25751123
Drug: Nonspecific treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonspecific treatment factors in child and parent sessions
Trial: 25751123
Drug: Nonspecific treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonspecific treatment factors in parent intervention
Trial: 17117692
Drug: Mitomycin C
RxNorm normalized name: Mitomycin C
DrugBank: Mitomycin (DB00305)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mitomycin C (0.4 mgr/0.2 ml) applied in 150 patients for 5 minutes during surgery
Trial: 15001969
Drug: 200 mL
RxNorm normalized name: Bag Top-Fill, 1200 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mL normal-strength orange juice
Trial: 11286609
Drug: Baclofen (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baclofen (40 mg maximum daily dose, given three times per day)
Trial: 11286609
Drug: Clonidine (0.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clonidine (0.8 mg maximum daily dose, given three times per day)
Trial: 8430057
Drug: metoprolol CR/ZOK
FDA approved: no
EMA approved: no
PMDA approved: no
Description: metoprolol CR/ZOK (95 mg metoprolol succinate)
Trial: 8430057
Drug: metoprolol OROS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: metoprolol OROS (95 mg metoprolol fumarate)
Trial: 8430057
Drug: immediate-release tablet
RxNorm normalized name: IR-3535
FDA approved: no
EMA approved: no
PMDA approved: no
Description: immediate-release tablet (100 mg metoprolol tartrate)
Trial: 26034150
Drug: Pregabalin (optimized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pregabalin (optimized to 300 or 450 mg/day)
Trial: 23824561
Drug: Early referral
RxNorm normalized name: teferrol
DrugBank: Iron polymaltose (DB15763)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early referral for psychosocial treatment
Trial: 21798429
Drug: Acetylsalicylic acid
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acetylsalicylic acid (ASA) 5 mg/kg/day
Trial: 21798429
Drug: Heparin/warfarin (started
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin/warfarin (started within 24 h of heparin lead-in; target INR: 2.0 to 3.0)
Trial: 21798429
Drug: Both ASA
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Both ASA and heparin/warfarin
Trial: 19205162
Drug: Cognitive-behavioral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral therapy (CBT) for tinnitus, 8 weeks duration
Trial: 14616414
Drug: Cimetidine 400
RxNorm normalized name: cimetidine 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine 400 mg twice daily with voriconazole 200 mg twice daily
Trial: 14616414
Drug: Ranitidine 150
RxNorm normalized name: ranitidine 150 MG
DrugBank: Ranitidine (DB00863)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ranitidine 150 mg twice daily with voriconazole 200 mg twice daily
Trial: 14616414
Drug: Placebo with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo with voriconazole 200 mg twice daily
Trial: 10800240
Drug: Inhalation sedation
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation sedation
Trial: 8833544
Drug: Biperiden lactate
RxNorm normalized name: biperiden lactate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biperiden lactate (4 mg)
Trial: 3883170
Drug: Placebo tablets
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets for six weeks
Trial: 31305464
Drug: GLP-1 receptor
RxNorm normalized name: GLP-1 receptor agonist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GLP-1 receptor agonist (GLP-1RA) treatment for 6 months
Trial: 29361042
Drug: Acetyl-L-Carnitine (ALC)
RxNorm normalized name: acetyl-L-carnitine
DrugBank: Acetylcarnitine (DB08842)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetyl-L-Carnitine (ALC) 1000 mg three times a day for 24 weeks
Trial: 17392729
Drug: Cranberry juice
RxNorm normalized name: cranberry juice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cranberry juice (200 ml t.i.d. for 10 days)
Trial: 16334158
Drug: 111In-HMFG1-F(ab')2 with
RxNorm normalized name: Crotalidae immune F(ab')2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 111In-HMFG1-F(ab')2 with lysine co-infusion
Trial: 16334158
Drug: 111In-HMFG1-F(ab')2 without
RxNorm normalized name: 111In-Pentetreotide
DrugBank: Indium In-111 pentetreotide (DB11835)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 111In-HMFG1-F(ab')2 without lysine co-infusion
Trial: 12468959
Drug: Terlipressin (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terlipressin (1 mg/4 h intravenously for 7 days)
Trial: 20337077
Drug: Two-visit endodontic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two-visit endodontic treatment
Trial: 22379833
Drug: Dahuangzhechong pills
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dahuangzhechong pills
Trial: 19646862
Drug: Epoetin beta
RxNorm normalized name: Epoetin beta
DrugBank: Epoetin beta (DB19434)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Epoetin beta without antithrombotic therapy
Trial: 19646862
Drug: Epoetin beta
RxNorm normalized name: Epoetin beta
DrugBank: Epoetin beta (DB19434)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Epoetin beta with antithrombotic therapy
Trial: 16456674
Drug: 6 g
RxNorm normalized name: FAPi-46 GA-68
DrugBank: FAPi-46 GA-68 (DB18827)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 g EAA mixture
Trial: 16456674
Drug: CHO +
RxNorm normalized name: G-CSF (CHO cell derived)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CHO + EAA supplement
Trial: 14743972
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose theophylline (USRT)
Trial: 14743972
Drug: Multiple doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple doses theophylline (USRT)
Trial: 11185672
Drug: Fixed-combination metformin/glyburide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed-combination metformin/glyburide tablets (500 mg/2.5 mg and 500 mg/5 mg)
Trial: 11185672
Drug: Metformin/glyburide (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin/glyburide (500 mg/5 mg) tablet with food
Trial: 11185672
Drug: Metformin/glyburide (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin/glyburide (500 mg/5 mg) tablet in fasted condition
Trial: 9382122
Drug: Ibandronate 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibandronate 0.5 mg
Trial: 9382122
Drug: Ibandronate 1
RxNorm normalized name: ibandronate 150 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibandronate 1 mg
Trial: 12006327
Drug: Ibandronate (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibandronate (all doses)
Trial: 9382122
Drug: Ibandronate (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibandronate (2 mg)
Trial: 1550171
Drug: Transdermal continuous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal continuous 17 beta‐estradiol, 0.05 mg/day, with transdermal cyclic norethindrone acetate, 0.25 mg/day
Trial: 1550171
Drug: Oral continuous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral continuous conjugated equine estrogens, 0.625 mg/day, with oral cyclic dl‐norgestrel, 0.15 mg/day
Trial: 3560612
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg nifedipine (corinfar)
Trial: 3560612
Drug: 80 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 mg propranolol (anaprilin)
Trial: 3560612
Drug: 60 mg
RxNorm normalized name: opium 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg propranolol and 20 mg nifedipine
Trial: 3560612
Drug: 80 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 mg propranolol (anaprilin) and 30 mg nifedipine (corinfar)
Trial: 31056685
Drug: Probiotics (Lactobacillus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotics (Lactobacillus paracasei, Lactobacillus rhamnosus, Lactobacillus acidophilus, Bifidobacterium lactis, 109 colony‐forming units per capsule) for 8 weeks
Trial: 24370154
Drug: 240‐mg/mL contrast
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 240‐mg/mL contrast material at 80 kVp
Trial: 24370154
Drug: 300‐mg/mL contrast
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300‐mg/mL contrast material at 80 kVp
Trial: 24370154
Drug: 370‐mg/mL contrast
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 370‐mg/mL contrast material at 120 kVp
Trial: 22943970
Drug: DA-1229 10
RxNorm normalized name: DAS-181
DrugBank: DAS-181 (DB15313)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DA-1229 10 mg after a high-fat meal
Trial: 22943970
Drug: DA-1229 (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DA-1229 (various doses: 1.25, 2.5, 5, 10, 20, 40, 60 mg)
Trial: 22943970
Drug: DA-1229 (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DA-1229 (various doses)
Trial: 11605809
Drug: Ceftibuten 200
RxNorm normalized name: ceftibuten 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftibuten 200 mg twice daily
Trial: 2653175
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg naloxone hydrochloride
Trial: 2653175
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg naloxone hydrochloride
Trial: 2653175
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg naloxone hydrochloride (single blind)
Trial: 794422
Drug: Inactivated Mycoplasma
RxNorm normalized name: Mycoplasma pneumoniae
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactivated Mycoplasma pneumoniae vaccine, 1-ml dose administered by jet-injection device.
Trial: 794422
Drug: Phosphate-buffered saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phosphate-buffered saline (placebo) administered similarly to control subjects.
Trial: 794422
Drug: Inactivated Mycoplasma
RxNorm normalized name: Mycoplasma pneumoniae
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactivated Mycoplasma pneumoniae vaccine
Trial: 26252534
Drug: ASM-024 50
RxNorm normalized name: Asm-024 cation
DrugBank: Asm-024 cation (DB19385)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ASM-024 50 mg
Trial: 26252534
Drug: ASM-024 200
RxNorm normalized name: Asm-024 cation
DrugBank: Asm-024 cation (DB19385)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ASM-024 200 mg
Trial: 21727232
Drug: Escitalopram (12-week
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Escitalopram (12-week treatment)
Trial: 21727232
Drug: Placebo (12-week
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (12-week treatment)
Trial: 16732081
Drug: Intravenous fructose
RxNorm normalized name: Fructose
DrugBank: Fructose (DB04173)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous fructose infusion (0.5 g . kg(‐1) . h(‐1) for 4 h, starting 3 h before induction of anesthesia)
Trial: 16732081
Drug: Intravenous fructose
RxNorm normalized name: Fructose
DrugBank: Fructose (DB04173)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous fructose infusion
Trial: 9228213
Drug: Minocycline 100
RxNorm normalized name: minocycline 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Minocycline 100 mg per day
Trial: 22089105
Drug: Hydrochlorothiazide (HCTZ)
RxNorm normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide (HCTZ) monotherapy for 9 weeks
Trial: 22089105
Drug: Atenolol monotherapy
RxNorm normalized name: Atenolol
DrugBank: Atenolol (DB00335)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atenolol monotherapy for 9 weeks
Trial: 22089105
Drug: Add-on therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Add-on therapy with HCTZ after atenolol
Trial: 22089105
Drug: Add-on therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Add-on therapy with atenolol after HCTZ
Trial: 16199188
Drug: TKA731 (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TKA731 (150 mg daily)
Trial: 15206646
Drug: Betaxolol 0.50%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Betaxolol 0.50% twice daily
Trial: 11775949
Drug: Mifepristone 300
RxNorm normalized name: mifepristone 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mifepristone 300 mg plus misoprostol 1,200 micrograms over 6 days
Trial: 11775949
Drug: Mifepristone 150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mifepristone 150 mg plus misoprostol 600 micrograms over 3 days
Trial: 8721493
Drug: Histamine injections
DrugBank: Histamine (DB05381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Histamine injections (0.1 micrograms each)
Trial: 1807007
Drug: Sulindac (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulindac (100 mg x 3 per day)
Trial: 1807007
Drug: Diclofenac sodium
RxNorm normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Diclofenac sodium (25 mg x 3 per day)
Trial: 1807007
Drug: Nifedipine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine (20 mg x 2 per day in slow releasing form)
Trial: 6338381
Drug: 10-drug regimen
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 10-drug regimen (modified LSA2-L2)
Trial: 6338381
Drug: 4-drug regimen
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 4-drug regimen (COMP)
Trial: 25795948
Drug: Cowpea protein
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cowpea protein isolate (25 g/day)
Trial: 25795948
Drug: Casein (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Casein (25 g/day)
Trial: 23348922
Drug: Novel anticoagulants
RxNorm normalized name: CPDA-1 Anticoagulant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Novel anticoagulants (specific types not mentioned) in PROBE trials
Trial: 23348922
Drug: Novel anticoagulants
RxNorm normalized name: CPDA-1 Anticoagulant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Novel anticoagulants (specific types not mentioned) in double-blind trials
Trial: 23348922
Drug: Warfarin (VKA)
DrugBank: Warfarin (DB00682)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Warfarin (VKA) control in PROBE trials
Trial: 23348922
Drug: Warfarin (VKA)
DrugBank: Warfarin (DB00682)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Warfarin (VKA) control in double-blind trials
Trial: 25473213
Drug: Polydeoxyribonucleotide (PDRN)
RxNorm normalized name: Adenine Deoxyribonucleoside
DrugBank: Adenosine (DB00640)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Polydeoxyribonucleotide (PDRN) administered intramuscularly (1 ampule, 3 mL, 5.625 mg, for 5 days) for 2 weeks and perilesionally (1 ampule, 3 mL, 5.625 mg, twice a week) for 4 weeks
Trial: 11379344
Drug: Bionormalizer (18
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bionormalizer (18 g/day for 2 weeks)
Trial: 1091127
Drug: Clofibrate (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clofibrate (2 gm. daily)
Trial: 28600953
Drug: Manualized cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manualized cognitive therapy (mCT)
Trial: 28600953
Drug: Cognitive-behavioral treatment-as-usual
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral treatment-as-usual (CBTAU)
Trial: 26082625
Drug: SFC 50/500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SFC 50/500 μg twice daily
Trial: 23365106
Drug: WL+FAEE (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: WL+FAEE (4 g/d Omacor)
Trial: 21274983
Drug: Erythromycin (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythromycin (1000 mg)
Trial: 10947692
Drug: Propofol 3
RxNorm normalized name: fospropofol 35 mg/mL intravenous solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol 3 mg.kg‐1 and succinylcholine 1 mg.kg‐1 (n = 40)
Trial: 10947692
Drug: Propofol 3
RxNorm normalized name: fospropofol 35 mg/mL intravenous solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol 3 mg.kg‐1 and alfentanil 10 microg.kg‐1 (n = 40)
Trial: 10947692
Drug: Propofol 3
RxNorm normalized name: fospropofol 35 mg/mL intravenous solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol 3 mg.kg‐1 and succinylcholine 1 mg.kg‐1 or Sevoflurane 8%
Trial: 8997677
Drug: CC +
RxNorm normalized name: CC
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CC + GTR
Trial: 1635933
Drug: Divitabs (sustained
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Divitabs (sustained release preparation)
Trial: 1635933
Drug: Normal carbamazepine
RxNorm normalized name: Carbamazepine
DrugBank: Carbamazepine (DB00564)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Normal carbamazepine preparation
Trial: 26879069
Drug: High-dose rosuvastatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose rosuvastatin (20 mg/day, n = 18)
Trial: 26879069
Drug: Low-dose rosuvastatin
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose rosuvastatin (2.5 mg/day, n = 19)
Trial: 26879069
Drug: Comparison of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison of high-dose vs low-dose rosuvastatin
Trial: 23065047
Drug: Topical antiglaucoma
RxNorm normalized name: ANTIGLAUCOMA MEDICATIONS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical antiglaucoma medication